Orthofix Readies For Bone Protein Product; Cites Hurdles For Acceptance
This article was originally published in The Gray Sheet
Orthofix is exploring the possibility of conducting clinical trials with its electrical stimulation products and Medtronic's InFuse BMP-2 to demonstrate a benefit for bone morphogenetic protein when used in conjunction with e-stim
You may also be interested in...
Orthofix will gain access to Breg Inc.'s sales and distribution relationships with general orthopedic offices as part of a $150 mil. acquisition to expand into spinal, reconstruction and trauma orthopedic franchises
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.